Abstract
Introduction: We previously demonstrated that 48 weeks of ADV therapy reduced intrahepatic HBV cccDNA by a median of 86% (p=0.002 vs. placebo) in CH-B patients and was correlated with significant reductions in serum and intracellular HBV DNA (HEPATOLOGY 2002;36: 296A). Since HBV cccDNA is the transcriptional template for HBsAg, we investigated whether reductions in cccDNA translated into significant reductions in serum HBsAg titer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
